title: Unintended consequences--the cost of preventing preterm births after FDA approval of a branded version of 17OHP.
authors.affiliation: Women's Health Division, Aetna, Sugar Land, TX, USA.
authors.forename: Joanne
authors.initials: J
authors.lastname: Armstrong
mesh_terms: D000077713:17 alpha-Hydroxyprogesterone Caproate; D017277:Drug Approval; D004339:Drug Compounding; D016527:Drug Costs; D005260:Female; D017048:Health Care Costs; D006801:Humans; D006908:Hydroxyprogesterones / Q000191:economics* / Q000627:therapeutic use; D007752:Obstetric Labor, Premature / Q000188:drug therapy; D010330:Patents as Topic; D011247:Pregnancy; D047928:Premature Birth / Q000517:prevention & control*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D006908:Hydroxyprogesterones; D000077713:17 alpha-Hydroxyprogesterone Caproate